Showing results (341-350 of 426) with videos related to

Sort By:
Pageof 43
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Hepatology (Baltimore, Md.)|November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based ApproachGuohong Han, Sarah Berhane, Hidenori Toyoda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational studyThomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology|December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinomaSirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications|October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational studyVincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Cancers|December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabYue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.
Pageof 43